August 9, 2004

FOR: ZOLL Medical Corporation

Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832



CHELMSFORD, MASS  Monday, August 09, 2004 – ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and software solutions, announced today that it has obtained an exclusive license for new software from the Institute of Critical Care Medicine, an international non-profit research center in Palm Springs. This software will be integrated into future versions of the ZOLL AED Plus™ automated external defibrillator (AED). When integrated, this software is expected to improve the accuracy of administering CPR and defibrillation to sudden cardiac arrest (SCA) victims. The software can determine whether CPR should be performed before defibrillation and, according to the Institute’s research, has been shown to predict successful defibrillation with a likelihood exceeding 90 percent accuracy. Improving the delivery of these early therapies may increase sudden cardiac arrest survival rates, which are currently at a low of 5 percent.

Software co-inventor Max Harry Weil, M.D., President of the Institute and Distinguished University Professor said, “The AED Plus, when equipped with this new software, should be more effective because rescuers will improve the success of the first defibrillating shock, if necessary. This software development further advances the Institute’s goal of expanding AEDs to become intelligent ‘resuscitation boxes,’ which can provide even untrained rescuers with valuable prompting of how—and when—to perform CPR and/or defibrillation. These developments represent an ongoing effort by the Institute to improve the very disappointing survival rates among the more than 460,000 cases of cardiac arrest in the U.S. alone.” The Institute’s Biomedical Engineering Vice President Jose Bisera, and Biomedical Engineers Clayton Young and Carlos Castillo directed the research, which led to the patented inventions found in the software.

“This agreement will allow ZOLL to enhance future product offerings so that rescuers can potentially have more success when using defibrillators, which can help increase survival rates. Once in cardiac arrest, every minute counts to get the heart beating normally again, and for every minute that passes, the chance of survival decreases by 10 percent,” said Richard A. Packer, President and Chief Executive Officer of ZOLL.

While early defibrillation is considered the most important factor for reviving SCA victims with ventricular fibrillation, prehospital studies appearing in The Journal of the American Medical Association in 1999 and 2003, found that the return of spontaneous circulation and survival increased when defibrillation was administered only after ambulance personnel had given CPR to patients that had been down for more than 3-5 minutes. Additionally, multiple studies directed by Wanchun Tang, M.D., Professor and Executive Vice President of the Institute, demonstrated that a defibrillating shock, when performed correctly, increases the likelihood that SCA victims will survive with less chance of brain injury.

About the Institute of Critical Care Medicine
The Institute of Critical Care Medicine was founded in 1961 at the University of Southern California (USC) by cardiologists Max Harry Weil, M.D., and the late Herbert Shubin, M.D., as a non-profit public foundation at the University of Southern California School of Medicine. The Institute is recognized as a comprehensive international center for research, study, and information in the medical, technical, ethical, and health economics fields as they pertain to immediate, life-saving medical care. It provides in-house and external programs through affiliations with medical centers throughout the world. Dr. Weil, who holds professorial appointments at USC and Northwestern University in Chicago, is a Rancho Mirage resident. The Institute established its international headquarters in Palm Springs in 1994. The Institute of Critical Care Medicine will move to larger quarters under construction in Rancho Mirage next November.

In the late 1990s, the Institute played a major role in the development of AEDs, and pioneered their introduction at diverse locations throughout the Coachella Valley including city halls, country clubs, senior centers, and theaters. To date, instructors from the Institute have trained more than 4,500 high school and middle school students in CPR and AED usage.

About ZOLL Medical Corporation
ZOLL Medical Corporation (NASDAQ: ZOLL) designs, manufactures, markets, and/or sells non-invasive resuscitation devices and software solutions. They include pacing and defibrillation devices (ZOLL’s M Series™ and AED Plus™, and LIFECOR, Inc.’s LifeVest™ and Life-Padz™ WCD 3000S Wearable Defibrillators), circulatory assist devices (Advanced Circulatory Systems, Inc.’s ResQPOD® Circulatory Enhancer and Revivant Corporation’s AutoPulse™); and a fluid resuscitation product called the Power Infuser®, manufactured by Infusion Dynamics, a division of ZOLL. These devices help healthcare professionals, emergency medical service providers, and first responders diagnose and treat victims of trauma, as well as sudden cardiac arrest.

Additionally, through its subsidiary ZOLL Data Systems, ZOLL designs and markets software that automates the collection and management of both clinical and non-clinical data. With direct operations, international offices, and business partners in all of the world’s major markets, ZOLL markets and sells its products in more than 140 countries. For more information, visit or call +1 (978) 421-9655.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company’s business, our ability to differentiate our products from others on the market, and other statements contained herein regarding matters that are not historical facts, are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled "Risk Factors" in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 19, 2004.

Copyright © 2004 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AED Plus, Life-Padz, M Series, and Power Infuser are trademarks of ZOLL Medical Corporation. The LifeVest System is a trademark of LIFECOR, Inc. The ResQPOD is a registered trademark of Advanced Circulatory Systems, Inc. The AutoPulse Resuscitation System is a trademark of Revivant Corporation. ZOLL is a registered trademark of ZOLL Medical Corporation. All trademarks are property of their respective owners.